The role of incretin receptor agonists in the treatment of obesity.

Thomas Forst Christophe E M De Block Stephano Del Prato Sara Armani Juan Pablo Frias Anne Lautenbach Bernhard LudvikMarina MarinezChantal Mathieu Timo Dirk Müller Oliver Schnell

Published in: Diabetes, obesity & metabolism (2024)

Many dual and triple co-agonists are still in development, and more data are needed to assess the efficacy, safety and tolerability of these emerging therapies versus the established incretin-based therapies; however, data are promising, and further results are eagerly awaited.

Keyphrases

electronic health record
big data
metabolic syndrome
type diabetes
insulin resistance
weight loss
open label
randomized controlled trial
adipose tissue
high fat diet induced
deep learning
replacement therapy